Delpacibart braxlosiran

N/A

Report date: 2026/03/12 20:00:16

Base Information

Drug NameDelpacibart braxlosiran

Drug Alias NameDel-braxAOC1020

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate > Antibody-Oligonucleotide conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionDouble homeobox protein 4 inhibitorsAnti-Transferrin receptor protein 1

TargetsDouble homeobox protein 4Transferrin receptor protein 1

Therapy Area/IndicationsMuscular Dystrophy, FacioscapulohumeralMuscular DystrophiesFoot-and-Mouth Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesUnited Kingdom +[4]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesAvidity Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesAvidity Biosciences Inc

Inactive CompaniesN/A

Active IndicationsMuscular Dystrophy, FacioscapulohumeralMuscular DystrophiesFoot-and-Mouth Disease

Inactive IndicationsN/A

Other Information

ATC CodeN/A